Filing Details
- Accession Number:
- 0000899243-21-019456
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-05-14 06:15:44
- Reporting Period:
- 2021-05-11
- Accepted Time:
- 2021-05-14 06:15:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1827506 | Talaris Therapeutics Inc. | TALS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1070844 | A Stephen Schwarzman | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
| 1393818 | Blackstone Group Inc | 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
| 1404071 | L.l.c. Management Group Blackstone | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
| 1464694 | L.p. I Holdings Blackstone | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
| 1464695 | L.l.c. Gp I/Ii Holdings Blackstone | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
| 1484870 | L.p. Ii Holdings Blackstone | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
| 1597143 | Clarus Lifesciences Iii, L.p. | 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
| 1620148 | Clarus Ventures Iii Gp, L.p. | 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
| 1762202 | L.l.c. Iii Clarus Blackstone | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
| 1793311 | L.p. Gp Clarus Blackstone | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-05-11 | 4,859,812 | $0.00 | 4,859,812 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 690,150 | $0.00 | 690,150 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 276,060 | $0.00 | 276,060 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 557,546 | $0.00 | 557,546 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 363,433 | $0.00 | 363,433 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 670,347 | $0.00 | 670,347 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 134,047 | $0.00 | 134,047 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 130,236 | $0.00 | 820,386 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 52,094 | $0.00 | 328,154 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 105,213 | $0.00 | 662,759 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 68,582 | $0.00 | 432,015 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 126,499 | $0.00 | 796,846 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 25,296 | $0.00 | 159,343 | No | 4 | C | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 15,918 | $17.00 | 4,875,730 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 3,611 | $17.00 | 823,997 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 1,444 | $17.00 | 329,598 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 2,917 | $17.00 | 665,676 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 1,902 | $17.00 | 433,917 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 3,507 | $17.00 | 800,353 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2021-05-11 | 701 | $17.00 | 160,044 | No | 4 | P | Indirect | See Footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | C | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2021-05-11 | 26,000,000 | $0.00 | 4,859,812 | $0.00 |
| Common Stock | Series A-1 Convertible Preferred Stock | Disposition | 2021-05-11 | 3,692,307 | $0.00 | 690,150 | $0.00 |
| Common Stock | Series A-1 Convertible Preferred Stock | Disposition | 2021-05-11 | 1,476,924 | $0.00 | 276,060 | $0.00 |
| Common Stock | Series A-1 Convertible Preferred Stock | Disposition | 2021-05-11 | 2,982,874 | $0.00 | 557,546 | $0.00 |
| Common Stock | Series A-1 Convertible Preferred Stock | Disposition | 2021-05-11 | 1,944,371 | $0.00 | 363,433 | $0.00 |
| Common Stock | Series A-1 Convertible Preferred Stock | Disposition | 2021-05-11 | 3,586,364 | $0.00 | 670,347 | $0.00 |
| Common Stock | Series A-1 Convertible Preferred Stock | Disposition | 2021-05-11 | 717,160 | $0.00 | 134,047 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2021-05-11 | 696,767 | $0.00 | 130,236 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2021-05-11 | 278,707 | $0.00 | 52,094 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2021-05-11 | 562,891 | $0.00 | 105,213 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2021-05-11 | 366,918 | $0.00 | 68,582 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2021-05-11 | 676,774 | $0.00 | 126,499 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2021-05-11 | 135,334 | $0.00 | 25,296 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of the Issuer's Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted on a 1-for-5.35 basis into common stock of the Issuer upon the closing of the Issuer's initial public offering.
- Reflects securities held directly by Clarus Lifesciences III, L.P. Clarus Ventures III GP, L.P. is the general partner of Clarus Lifesciences III, L.P. Blackstone Clarus III L.L.C. is the general partner of Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P.
- Reflects securities held directly by Clarus Defined Exit I, L.P.
- Reflects securities held directly by Clarus DE II, L.P.
- Reflects securities held directly by Clarus IV-A, L.P.
- Reflects securities held directly by Clarus IV-B, L.P.
- Reflects securities held directly by Clarus IV-C, L.P.
- Reflects securities held directly by Clarus IV-D, L.P.
- Clarus Ventures DE GP, L.P. is the general partner of each of Clarus Defined Exit I, L.P. and Clarus DE II, L.P. Blackstone Clarus DE L.L.C. is the general partner of Clarus Ventures DE GP, L.P. The sole member of Blackstone Clarus DE L.L.C. is Blackstone Holdings II L.P.
- Clarus IV GP, L.P. is the general partner of each of Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P. and Clarus IV-D, L.P. Blackstone Clarus GP L.P. is the general partner of Clarus IV GP, L.P. Blackstone Clarus GP L.L.C. is the general partner of Blackstone Clarus GP L.P. The sole member of Blackstone Clarus GP L.L.C. is Blackstone Holdings I L.P.
- The general partner of each of Blackstone Holdings I L.P. and Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is The Blackstone Group Inc. The sole holder of the Series II preferred stock of The Blackstone Group Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.
- Due to the limitations of the electronic filing system certain Reporting Persons are filing a separate Form 3.
- Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.
- Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Billionaire Hedge Funds
